Platelet mTOR Pathway Drives Neuropathogenesis in Cerebral Malaria

Understanding Neuropathogenesis in Cerebral Malaria

Malaria, a parasitic disease caused by Plasmodium species, remains a significant global health burden, causing hundreds of thousands of deaths annually. Cerebral malaria represents a leading cause of this mortality and subsequent neurological sequelae [1]. This severe manifestation is characterized by brain swelling and elevated intracranial pressure, factors strongly associated with fatal outcomes in children [2]. The underlying pathology involves a complex interplay of inflammation and endothelial dysfunction within the central nervous system, which impairs cerebral blood flow and increases vascular permeability [3, 4]. Platelets are known to contribute to this process by accumulating in the brain's microvasculature and promoting obstruction, yet the precise molecular drivers have been poorly defined [1, 5]. A recent study provides new mechanistic details on a key signaling pathway within platelets that contributes directly to malaria-associated neuropathogenesis.

Platelet mTOR: A Central Player in Malaria Pathogenesis

To investigate the molecular basis of platelet involvement in cerebral malaria, researchers focused on the mechanistic target of rapamycin (mTOR) pathway, a critical intracellular signaling network that regulates cellular growth, metabolism, and survival. The study first sought to determine if this pathway becomes active in platelets during malaria infection. The results confirmed mTOR pathway activation in platelets under both laboratory and live-animal conditions. In an ex vivo model, co-incubation of platelets with Plasmodium falciparum-infected red blood cells was sufficient to trigger the pathway. This finding was corroborated in vivo, where mTOR signaling was also activated in the platelets of mice infected with Plasmodium berghei ANKA (PbA). This consistent activation across different models suggests that platelet mTOR is a key component of the host response to malaria, setting the stage for downstream pathological events in the brain.

Targeting Platelet mTOR Improves Outcomes in Experimental Cerebral Malaria

Having established that the mTOR pathway is activated in platelets during infection, the investigators next tested whether inhibiting this pathway could alter the course of the disease. They used a mouse model in which the mTOR gene was specifically deleted only in platelets (mTORplt-/-). When these mice were infected with the parasite that causes experimental cerebral malaria, they exhibited significantly increased survival compared to control mice with functional platelet mTOR. This survival advantage points to platelet mTOR as a critical mediator of lethality in this disease model. Importantly, this improved survival was not a result of changes in parasite burden or platelet counts; the researchers found the benefits were independent of both parasitemia and thrombocytopenia. This suggests that targeting platelet mTOR offers a potential host-directed therapeutic strategy that could mitigate severe neurological damage without directly targeting the parasite, making it a possible adjunct to standard antimalarial drugs.

Mechanism of Action: Reduced Brain Platelet Deposition and Improved Cerebral Perfusion

To understand how the absence of platelet mTOR conferred a survival benefit, the researchers examined the brains of the infected mice. Their analysis revealed that the PbA-infected mTORplt-/- mice had significantly reduced platelet deposition in the brain compared to controls. This directly implicates the mTOR pathway in the pathological accumulation of platelets within the cerebral microvasculature, a known hallmark of cerebral malaria. This reduction in platelet aggregation led to tangible physiological improvements. The mice with mTOR-deficient platelets demonstrated improved cerebral blood flow, suggesting less microvascular obstruction and a reduced risk of ischemic injury. Furthermore, these mice also showed reduced brain vascular permeability, indicating that the integrity of the blood-brain barrier was better maintained. Together, these findings provide a clear mechanism: platelet mTOR activation drives the vascular blockage and leakage that cause the severe neurological complications of cerebral malaria.

Heme-Induced ITAM Signaling Drives Platelet mTOR Activation

The investigation then aimed to identify the upstream trigger for this pathological cascade. The researchers focused on heme, a pro-inflammatory molecule released in large quantities from red blood cells lysed by the malaria parasite. They discovered that in control mice, plasma heme levels correlated significantly with the degree of intracerebral platelet accumulation. This finding establishes a direct link between parasite-induced hemolysis and the platelet-driven brain pathology. Strikingly, this correlation was absent in the mTORplt-/- mice, confirming that the mTOR pathway is essential for mediating heme's pathological effects on platelets in the brain. Subsequent in vitro experiments detailed the molecular mechanism, showing that heme activates platelet mTOR through a pathway known as Immunoreceptor Tyrosine-based Activation Motif (ITAM) signaling, a common activation cascade in immune cells. This process was found to occur predominantly through a specific cell-surface receptor, the C-type lectin-like receptor 2. This detailed molecular map identifies precise targets for disrupting the platelet activation central to cerebral malaria.

Therapeutic Implications: Blocking Heme-Induced Platelet Activation

Based on their mechanistic findings, the researchers tested a potential therapeutic strategy aimed at the newly identified pathway. They found that using cobalt protoporphyrin, an agent that blocks heme-induced platelet activation, significantly reduced platelet mTOR activation in their experimental model. This molecular inhibition translated directly to a clinical benefit, as treatment with cobalt protoporphyrin also decreased mortality associated with experimental cerebral malaria. The study's findings present a cohesive model in which platelet mTOR amplifies the platelet activation responses initiated by heme. The authors conclude that the deletion of platelet mTOR reduces platelet deposition in the brain, thereby preventing the downstream consequences of microvascular obstruction and increased permeability. This work suggests that inhibiting the heme-mTOR axis in platelets impedes the progression of symptomatic disease and could represent a viable strategy for developing new therapies to reduce mortality from cerebral malaria.

References

1. Portier I, Denorme F, Tolley ND, et al. Heme-induced ITAM signaling exacerbates malaria-associated neuropathogenesis through activation of platelet mTOR.. Blood. 2026. doi:10.1182/blood.2025030841

2. Seydel KB, Kampondeni S, Valim C, et al. Brain Swelling and Death in Children with Cerebral Malaria. New England Journal of Medicine. 2015. doi:10.1056/nejmoa1400116

3. Chen L, Deng H, Cui H, et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2017. doi:10.18632/oncotarget.23208

4. Jin Y, Ji W, Yang H, Chen S, Zhang W, Duan G. Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches. Signal Transduction and Targeted Therapy. 2020. doi:10.1038/s41392-020-00454-7

5. Mayhew JA, Witten AJ, Bond CA, et al. Cytomegalovirus reactivation and acute and chronic complications in children with cerebral malaria: a prospective cohort study.. Malaria journal. 2025. doi:10.1186/s12936-025-05293-x